Receptor-mediated tumor targeting based on peptide hormones.
about
The novel fusion proteins, GnRH-p53 and GnRHIII-p53, expression and their anti-tumor effectProtein expression profile of HT-29 human colon cancer cells after treatment with a cytotoxic daunorubicin-GnRH-III derivative bioconjugateLuteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomesCo-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy.Integrin targeting for tumor optical imagingTargeted tumor therapy by Rubia tinctorum L.: analytical characterization of hydroxyanthraquinones and investigation of their selective cytotoxic, adhesion and migration modulator effects on melanoma cell lines (A2058 and HT168-M1).Peptide receptor targeting in cancer: the somatostatin paradigm.Trigonal scaffolds for multivalent targeting of melanocortin receptors.Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice.Octreotide-functionalized and resveratrol-loaded unimolecular micelles for targeted neuroendocrine cancer therapy.Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.Molecular-targeted approaches to reduce renal accumulation of nephrotoxic drugs.Recent advances in ligand targeted therapy.Synthesis, drug release, and biological evaluation of new anticancer drug-bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety.Stability, permeability and growth-inhibitory properties of gonadotropin-releasing hormone liposaccharides.Photoresists as a high spatial resolution autoradiography substrate for quantitative mapping of intra- and sub-cellular distribution of Auger electron emitting radionuclides.Investigation of cancer cell lines for peptide receptor-targeted drug development.In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites.99m Tc-labeled NGR-chlorambucil conjugate, 99m Tc-HYNIC-CLB-c(NGR) for targeted chemotherapy and molecular imaging.Peptide-mediated vectorization of metal complexes: conjugation strategies and biomedical applications.Insights into structure-activity relationships of somatostatin analogs containing mesitylalanine.Somatostatin receptor-targeted organometallic iridium(iii) complexes as novel theranostic agents.Modification of daunorubicin-GnRH-III bioconjugates with oligoethylene glycol derivatives to improve solubility and bioavailability for targeted cancer chemotherapy.Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery.Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty acidsOn the selection and design of proteins and peptide derivatives for the production of photoluminescent, red-emitting gold quantum clusters
P2860
Q28534798-D952151C-5EF2-4211-AD03-EFA2C1D867EBQ28537657-F8763E63-BDFB-48F1-BAED-4156500F4EADQ34170191-9E551592-2C6E-4AAF-B159-AF05E6565FB8Q34446374-92FBBCC8-82AB-4AA5-9DDE-888579AC1392Q34912662-0F232351-30DE-4C05-9E86-3A64F6726959Q35874369-82BCC1F8-3C0C-40F2-9686-077A344D0D97Q36638046-FC158DE4-77A0-4C3F-A4EF-2A4373BD430EQ36658378-E420B25C-11FB-4601-BBDD-1F1F550F75F7Q37034254-E48144AA-D280-4124-8CB2-CE67064F2D2DQ37403020-C53B90A3-6A8B-4863-A57C-A566C36B1FB0Q37696327-32B70ED2-F9FA-4BFE-85B0-CD73BD05315FQ37763924-386E7519-2D06-4C39-88D3-FFB5DF63616AQ37937611-59DA1A3D-9120-409D-B07B-F7270C8BE1F3Q38865705-BD4A2BEC-1310-4336-BE5D-06FE7A08F497Q38939445-E0F998DC-09F7-4C02-A356-1AA0216EB8BDQ39302746-8E930203-5571-4F34-ACFB-7BD22D54BCF7Q39492350-8EEE5FA1-2FC4-435D-9E64-399AE68693AFQ39643108-7D5275B0-C71B-4169-993E-D1E26FB35F12Q48091368-4B8E2262-B981-42BD-AF0B-A44F0087F37DQ50860069-4997D5B9-34C2-4E35-B91C-CED5EE728FD3Q51751002-A8FD708A-7B05-4879-A962-D731A4D8E0E8Q52662227-E76598B7-A6A0-4C53-B09D-EA33E1E35951Q53589895-7353F30C-D8CF-4D6B-AEB3-28CBDCE8FA66Q55082165-E3A387E6-BCB8-4047-8A84-03472146AE48Q57821212-D12CDFE0-2F5E-4886-8407-EC613DCFA46CQ58310814-200213A5-3DDA-4086-B059-D12A878C5C7A
P2860
Receptor-mediated tumor targeting based on peptide hormones.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Receptor-mediated tumor targeting based on peptide hormones.
@en
Receptor-mediated tumor targeting based on peptide hormones.
@nl
type
label
Receptor-mediated tumor targeting based on peptide hormones.
@en
Receptor-mediated tumor targeting based on peptide hormones.
@nl
prefLabel
Receptor-mediated tumor targeting based on peptide hormones.
@en
Receptor-mediated tumor targeting based on peptide hormones.
@nl
P2860
P1476
Receptor-mediated tumor targeting based on peptide hormones.
@en
P2093
Gábor Mezo
Marilena Manea
P2860
P356
10.1517/17425240903418410
P407
P577
2010-01-01T00:00:00Z